Showing 5191-5200 of 5771 results for "".
- Avellino Labs to Provide Corporate and Technology Updates at OIS and ASCRS in San Diegohttps://modernod.com/news/avellino-labs-to-provide-corporate-and-technology-updates-at-ois-and-ascrs-in-san-diego/2476522/Executives from Avellino Labs will be presenting at several events during the American Society of Cataract and Refractive Surgery annual meeting at the San Diego Convention Center and nearby venues, May 2-5, 2019. Known for its successful introduction of the world’s first DNA test to
- LKC Technologies Launches New UTAS Systems at ARVOhttps://modernod.com/news/lkc-technologies-launches-new-utas-systems-at-arvo/2476520/LKC Technologies has announced the launch of new UTAS systems at the ARVO meeting in Vancouver (booth #1003). The UTAS SunBurst is a small, lightweight and easy to use system capable of conducting full ISCEV-complaint electroretinograms (ERGs), visual evoked potential (VEPs) tests, and ele
- Allegro to Present Results of Its ALG-1007 Ex-US Trial for Dry Eye Disease at ASCRShttps://modernod.com/news/allegro-to-present-results-of-its-alg-1007-ex-us-trial-for-dry-eye-disease-at-ascrs/2476519/Following last week’s news that the company is expanding its pipeline into dry eye and has created a new Cornea Scientific Advisory Board (Cornea SAB), Allegro Ophthalmics announced that the results of its ALG-1007 ex
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- LensGen Will Present Early Results Of International “Grail” Study At ASCRShttps://modernod.com/news/lensgen-will-present-early-results-of-international-grail-study-at-ascrs/2476515/LensGen will share results from its “Grail” study at the ASCRS annual meeting in San Diego, May 3-7. The results will include the latest available data on patients who have been treated at two international sites.
- Iridex’s MicroPulse Laser Technology Featured in Several Glaucoma and Retina Research Presentationshttps://modernod.com/news/iridexs-micropulse-laser-technology-featured-in-several-glaucoma-and-retina-research-presentations/2476514/Iridex announced that its patented MicroPulse technology played a pivotal role in research presented at the 2019 Association for Research in Vision & Ophthalmology (ARVO) and American Society of Cataract & Refractive Surgeons (ASCRS) meetings, to be held in Vancouver and San Diego, respec
- RadianceTx Expands Team to Develop Beta Ophthalmic Systemhttps://modernod.com/news/radiancetx-expands-team-to-develop-beta-ophthalmic-system/2476511/Radiance Therapeutics has announced the expansion of its core team. Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Business Development and Outreach. James Fazio, MBA, Msc Eng, formerly Global Business Leader for
- Implandata Gains CE Mark for its Eyemate System for Keratoprosthesishttps://modernod.com/news/implandata-gains-ce-mark-for-its-eyemate-system-for-keratoprosthesis/2476510/Ophthalmic sensors and digital health company Implandata Ophthalmic Products announced that it attained CE mark for its Eyemate system for use in patients undergoing keratoprosthesis surgery. Keratoprosthesis represents an infrequent yet important procedure for restoring vision. It is performed o
- Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the UShttps://modernod.com/news/santen-and-glaukos-enter-into-collaboration-and-distribution-agreement-for-exclusive-distribution-of-the-microshunt-de-128-in-the-us/2476507/Santen Pharmaceutical announced that its US subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt in the U.S. market. Financial
- New Data from Phase 3 Teprotumumab Trial Shows Reduction in Proptosis, or Eye Bulging, in Active Thyroid Eye Disease (TED)https://modernod.com/news/new-data-from-phase-3-teprotumumab-trial-shows-reduction-in-proptosis-or-eye-bulging-in-active-thyroid-eye-disease-ted/2476506/Horizon Pharma announced that new data from the phase 3 confirmatory clinical trial (OPTIC) evaluating the investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED) were presented